CAP-1002 is a cell therapy. It is an allogeneic product, meaning it is manufactured from donor heart tissue and then stored until needed for use. CAP-1002 consists of allogeneic cardiosphere-derived cells, a unique population of cells that contains cardiac progenitor cells. It is thought to decrease inflammation and muscle degeneration while exerting positive effects on muscle regeneration, all of which may translate into patients retaining muscle function for a longer period of time.
A Phase 3 study called Hope-3 is actively recruiting.
This program is sponsored by Capricor Therapeutics.
ACTIVELY RECRUITING | A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-3) |
OPEN LABEL EXTENSION | Open-label Extension of the HOPE-2 Trial (HOPE-2-OLE) |
JAN 2023 | Webinar: Capricor Data Update From Ongoing HOPE-2 Open Label Extension Trial (January 2023)Capricor Therapeutics joined PPMD for a community webinar on January 25, 2023 to present recent data findings from the ongoing HOPE-2 open label extension trial and provide an update to the community on the ongoing HOPE-3 clinical trial. |
JUNE 2022 | Capricor Therapeutics Presents at the PPMD 2022 Annual ConferenceLate Breaking News Session |
JUNE 2021 | Capricor Therapeutics Presents at the PPMD 2021 Virtual Annual ConferencePre-recorded content for PPMD's 2021 Virtual Annual Conference On-Demand Library |
JUNE 2020 | Webinar: Capricor's HOPE-2 Final 12-Month DataOn June 3, 2020, Capricor joined Parent Project Muscular Dystrophy for a webinar to discuss Capricor’s HOPE-2 clinical program, following the company’s announcement of positive final 12-month results from the HOPE-2 Trial. |
JULY 2019 | Webinar: Capricor’s HOPE-2 Interim AnalysisOn July 17, 2019, Capricor joined Parent Project Muscular Dystrophy for a webinar to update the community on Capricor’s HOPE-2 clinical program, following the company’s announcement of positive results from their interim analysis in the HOPE-2 Trial after placing a voluntary dosing hold earlier in the year. |
APRIL 2019 | Webinar: Capricor’s Clinical ProgramOn April 24, 2019, Capricor joined Parent Project Muscular Dystrophy for a webinar to update the community on Capricor’s HOPE2 clinical program. |
JULY 2018 | Webinar: HOPE-2 Duchenne Clinical Trial – CapricorPPMD and Capricor hosted a webinar on July 18, 2018 to discuss the HOPE-2 trial. Capricor provided a brief background of CAP-1002 and its clinical development to date that has led to this exciting trial. The webinar also reviewed the trial design, eligibility criteria, and assessments that participants will need to complete if they participate in the trial, as well as the travel policy for participants who need to travel to a trial site. |
JUNE 2018 | Capricor Presents at the PPMD 2018 Annual Conference |
NOV 2017 | Webinar: Capricor Therapeutics' HOPE-Duchenne Clinical TrialCapricor Therapeutics joined PPMD for a webinar on November 30, 2017 to discuss the 12-month results from Capricor's HOPE-Duchenne Clinical Trial, as well as the company’s plans for the HOPE-2 Clinical Trial in the first quarter of 2018, pending regulatory approval. |
APRIL 2017 | Webinar: Capricor Therapeutics' HOPE-Duchenne Clinical TrialParent Project Muscular Dystrophy, Coalition Duchenne, and Capricor hosted a webinar on April 28, 2017 to hear a community update on the six-month results from Capricor's randomized Phase I/II HOPE Clinical Trial of CAP-1002 (allogeneic cardiosphere-derived cells), an investigational candidate for the treatment of Duchenne. |
